生物试剂
>
生化试剂
>
分析化学
> 黄芪甲苷 促销
加入收藏 取消收藏

黄芪甲苷 促销  ≥98%(HPLC),分析标准品

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

件 库存{{model.attbuying.number}}件
立即购买 加入购物车 下载说明书

看了又看
包装规格：20mg in glass bottle
溶解性：熔点：295-296°C (lit.)
产品描述：基本信息 产品编号： A10426 产品名称： Astragaloside IV CAS: 84687-43-4   储存条件 粉末 -20℃ 四年     分子式： C41H68O14 溶于液体 -80℃ 两年 分子量 784.97 -20℃ 一个月 化学名：  Astragaloside IV, United States Pharmacopeia (USP) Reference Standard Solubility (25°C)：   体外:   DMSO 100mg/mL (127.39mM) Ethanol   Water   体内(现配现用): 1.请依序添加每种溶剂：10% DMSO→40% PEG300→5% Tween-80→45% saline Solubility: 2.5mg/mL (3.18mM); Suspended solution; Need ultrasonic 此⽅案可获得 2.5mg/mL (3.18mM) 的均匀悬浊液，悬浊液可⽤于⼝服和腹腔注射。 以 1mL ⼯作液为例，取 100μL 25.0mg/mL 的澄清 DMSO 储备液加到 400μL PEG300 中，混合均匀；向上述体系中加⼊ 50μL Tween-80，混合均匀；然后继续加⼊ 450μL ⽣理盐⽔定容⾄ 1mL。 2.请依序添加每种溶剂：10% DMSO→90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5mg/mL (3.18mM); Clear solution 此⽅案可获得 ≥ 2.5mg/mL (3.18mM，饱和度未知) 的澄清溶液。 以 1mL ⼯作液为例，取 100μL 25.0mg/mL 的澄清 DMSO 储备液加到 900μL 20% 的 SBE-β-CD ⽣理盐⽔⽔溶液中，混合均匀。 3.请依序添加每种溶剂：10% DMSO→90% corn oil Solubility: ≥ 2.5mg/mL (3.18mM); Clear solution 此⽅案可获得 ≥ 2.5mg/mL (3.18mM，饱和度未知) 的澄清溶液，此⽅案不适⽤于实验周期在半个⽉以上的实验。 以 1mL ⼯作液为例，取 100μL 25.0mg/mL 的澄清 DMSO 储备液加到 900μL ⽟⽶油中，混合均匀。 ＜1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。   制备储备液   浓度   溶液体积 质量   1mg   5mg   10mg 1mM 1.2739mL 6.3697mL 12.7393mL 5mM 0.2548mL 1.2739mL 2.5479mL 10mM 0.1274mL 0.6370mL 1.2739mL 50mM 0.0255mL 0.1274mL 0.2548mL   生物活性 产品描述 一种从黄芪中提取的主要活性成分，具有广阔的应用前景，特别是在心血管疾病、消化道疾病、癌症等现代高发病率、高危疾病中，可作为药物开发利用。黄芪甲苷的保护作用包括心血管系统、免疫系统、消化系统、神经系统，其作用机制与调节钙平衡、抗氧化、抗凋亡、抗病毒等有关。 靶点 JNK  ERK  Akt  mTOR  NF-κB  体外研究 Astragaloside IV (10, 20, 40ng/mL) inhibits NSCLC cell growth, whereas low concentrations of astragaloside IV (1, 2.5, 5ng/mL) has no obvious cytotoxicity on cell viability. Moreover, combined treatment with astragaloside IV significantly increases chemosensitivity to cisplatin in NSCLC cells. On the molecular level, astragaloside IV co-treatment significantly inhibits the mRNA and protein levels of B7-H3 in the presence of cisplatin. Astragaloside IV inhibits the viability and invasive potential of MDA-MB-231 breast cancer cells, suppresses the activation of the mitogen activated protein kinase (MAPK) family members ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2 and -9 体内研究 Astragaloside IV (10, 20mg/kg, p.o.) exhibits a potent ability to prevent cognitive deficits induced by transient cerebral ischemia and reperfusion. Astragaloside IV (10mg/kg) and Astragaloside IV (20mg/kg) can significantly decrease the levels of these cytokines compared to the Model group. Astragaloside IV significantly inhibits the level of TLR4 and its downstream proteins, suggesting that both MyD88-dependent and -independent pathways play important roles in the anti-inflammatory effects of Astragaloside IV. Astragaloside IV attenuates NLRP3 and cleaved-caspase-1 expression, and reduces Iba1 protein expression. In the mice model, the high-dose astragaloside IV group has a significant increase in the 48-hour survival rate [60% (9/15) vs 13.3% (2/15), P < 0.05], significant reductions in the serum ALT and AST levels (P < 0.01), and significant reductions in liver histopathological indices and the degree of apoptosis of hepatocytes (P < 0.01), as well as a significant reduction in the content of MDA in liver homogenate (P < 0.01) and a significant increase in the activity of SOD   推荐实验方法(仅供参考) Kinase Assay Briefly, MDA-MB-231 cells treated as indicated or tumor tissues are harvested and lysed inmg2+ lysis buffer containing 50mM Tris (pH 7.5), 10mMmgCl2, 0.5 M NaCl, and protease inhibitor cocktail. Equal amounts of lysates are incubated with PAK-PBD beads at 4°C for 1 h. PAK-PBD beads are pelleted by centrifugation and washed with ish buffer containing 25mM Tris (pH 7.5), 30mMmgCl2, 40mM NaCl. Active Rac1 is detected by western blotting.     Cell Assay Cell viability is determined by CCK-8 assay. To be brief, cultured NSCLC cells are seeded into 96-well plates at the density of 4×104 (cells/well). Then 10μL⁄well CCK8 solution is added and incubated in dark at 37°C for another 2 h. The absorbance is determined with the wavelength of 490 nm.     Animal Administration Transient cerebral ischemia and reperfusion is prepared by BCCAO, as BCCAO is considered an ideal model to study transient cerebral ischemia and reperfusion injury-mediated inflammatory response. Mice are randomLy divided into the Sham, Model, Astragaloside IV (10mg/kg) and Astragaloside IV (20mg/kg) treatment groups. The Astragaloside IV treatment groups are intragastrically administered 7 days before the surgery and terminated on the day of sacrifice. On the day of the surgery, Astragaloside IV is administrated 2 h prior to ischemia. The Sham-operated and Model groups are treated with distilled water. After the mice are anesthetized with an intraperitoneal injection of chloral hydrate (350mg/kg), the bilateral common carotid arteries are exposed and carefully separated with a small ventral neck incision and occluded twice (20 min each) with ligated surgical silk as described previously with minor modifications. There is a 10 min reperfusion period between the two occlusion periods (ischemia 20 min − reperfusion 10 min − ischemia 20 min). Sham-operated mice are subjected to the same surgical operation without the surgical silk ligation. Mouse body temperature is maintained at 37±0.5°C during the surgery with heating equipment until recovery from the anesthesia.
保存条件：-20℃

猜你喜欢